Literature DB >> 22226252

Meta-analysis of overnight closed-loop randomized studies in children and adults with type 1 diabetes: the Cambridge cohort.

Kavita Kumareswaran1, Daniela Elleri, Janet M Allen, Julie Harris, Dongyuan Xing, Craig Kollman, Marianna Nodale, Helen R Murphy, Stephanie A Amiel, Simon R Heller, Malgorzata E Wilinska, Carlo L Acerini, Mark L Evans, David B Dunger, Roman Hovorka.   

Abstract

AIM: We reviewed the safety and efficacy of overnight closed-loop insulin delivery compared with conventional continuous subcutaneous insulin infusion (CSII) in two distinct age groups with type 1 diabetes mellitus (T1DM), young people aged 5 to 18 years and adults, combining data of previously published randomized studies.
METHODS: We evaluated four randomized crossover studies in 17 children and adolescents [13.4 ± 3.6 years; mean ± standard deviation (SD)] and 24 adults (37.5 ± 9.1 years) on 45 closed-loop (intervention) and 45 CSII (control) visits. Each subject attended for two overnight study visits, using either closed-loop or conventional pump therapy, in random order. In each age group, studies were designed to mimic realistic likely scenarios. In the children and adolescent studies, closed loop was used following a standard evening meal and following 40 min of moderate-intensity exercise. In the adult studies, closed loop was commenced following a 60 g carbohydrate meal or a 100 g carbohydrate meal accompanied by alcohol. The primary outcome measure was time for which plasma glucose was within target range (3.91-8.0 mmol/liter).
RESULTS: Overnight closed loop increased the time in target plasma glucose in both young (from 40% to 60%, p = .002) and adults (from 50% to 76%, p < .001) compared with conventional CSII. Combined analysis showed an increase from 43% to 71% with closed loop (p < .001). Additionally, closed loop reduced the time spent below 3.91 mmol/liter and above 8.0 mmol/liter, from 4.1% to 2.1% (p = .01) and 33% to 20% (p = .03), respectively. Glycemic variability, as measured by the SD of plasma glucose, was lower during closed loop compared with CSII (1.5 versus 2.1 mmol/liter, p = .007).
CONCLUSIONS: Overnight closed loop may improve glycemic control and reduce nocturnal hypoglycemia in both young people and adults with T1DM.
© 2011 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22226252      PMCID: PMC3262701          DOI: 10.1177/193229681100500606

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  37 in total

1.  Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial.

Authors:  Roman Hovorka; Janet M Allen; Daniela Elleri; Ludovic J Chassin; Julie Harris; Dongyuan Xing; Craig Kollman; Tomas Hovorka; Anne Mette F Larsen; Marianna Nodale; Alessandra De Palma; Malgorzata E Wilinska; Carlo L Acerini; David B Dunger
Journal:  Lancet       Date:  2010-02-04       Impact factor: 79.321

Review 2.  Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy.

Authors:  Daniela Bruttomesso; Silvana Costa; Aldo Baritussio
Journal:  Diabetes Metab Res Rev       Date:  2009-02       Impact factor: 4.876

3.  Parental attitudes towards overnight closed-loop glucose control in children with type 1 diabetes.

Authors:  Daniela Elleri; Carlo L Acerini; Janet M Allen; Josephine Hayes; Claire Pesterfield; Malgorzata E Wilinska; David B Dunger; Roman Hovorka
Journal:  Diabetes Technol Ther       Date:  2010-01       Impact factor: 6.118

4.  Alcohol causes hypoglycaemic unawareness in healthy volunteers and patients with type 1 (insulin-dependent) diabetes.

Authors:  D Kerr; I A Macdonald; S R Heller; R B Tattersall
Journal:  Diabetologia       Date:  1990-04       Impact factor: 10.122

5.  MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes.

Authors:  Eran Atlas; Revital Nimri; Shahar Miller; Eli A Grunberg; Moshe Phillip
Journal:  Diabetes Care       Date:  2010-02-11       Impact factor: 19.112

6.  Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes.

Authors:  Jessica R Castle; Julia M Engle; Joseph El Youssef; Ryan G Massoud; Kevin C J Yuen; Ryland Kagan; W Kenneth Ward
Journal:  Diabetes Care       Date:  2010-03-23       Impact factor: 17.152

7.  Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy.

Authors:  Barbara E K Klein; Ronald Klein; Patrick E McBride; Karen J Cruickshanks; Mari Palta; Michael D Knudtson; Scot E Moss; Jennifer O Reinke
Journal:  Arch Intern Med       Date:  2004-09-27

Review 8.  A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education.

Authors:  Diane Wild; Robyn von Maltzahn; Elaine Brohan; Torsten Christensen; Per Clauson; Linda Gonder-Frederick
Journal:  Patient Educ Couns       Date:  2007-06-19

9.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

10.  Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.

Authors:  Roman Hovorka; Kavita Kumareswaran; Julie Harris; Janet M Allen; Daniela Elleri; Dongyuan Xing; Craig Kollman; Marianna Nodale; Helen R Murphy; David B Dunger; Stephanie A Amiel; Simon R Heller; Malgorzata E Wilinska; Mark L Evans
Journal:  BMJ       Date:  2011-04-13
View more
  7 in total

Review 1.  Multivariable Adaptive Artificial Pancreas System in Type 1 Diabetes.

Authors:  Ali Cinar
Journal:  Curr Diab Rep       Date:  2017-08-15       Impact factor: 4.810

2.  Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia.

Authors:  Marc Breton; Anne Farret; Daniela Bruttomesso; Stacey Anderson; Lalo Magni; Stephen Patek; Chiara Dalla Man; Jerome Place; Susan Demartini; Simone Del Favero; Chiara Toffanin; Colleen Hughes-Karvetski; Eyal Dassau; Howard Zisser; Francis J Doyle; Giuseppe De Nicolao; Angelo Avogaro; Claudio Cobelli; Eric Renard; Boris Kovatchev
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.461

3.  Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial.

Authors:  Roman Hovorka; Daniela Elleri; Hood Thabit; Janet M Allen; Lalantha Leelarathna; Ranna El-Khairi; Kavita Kumareswaran; Karen Caldwell; Peter Calhoun; Craig Kollman; Helen R Murphy; Carlo L Acerini; Malgorzata E Wilinska; Marianna Nodale; David B Dunger
Journal:  Diabetes Care       Date:  2014       Impact factor: 19.112

Review 4.  Closed-loop insulin delivery for treatment of type 1 diabetes.

Authors:  Daniela Elleri; David B Dunger; Roman Hovorka
Journal:  BMC Med       Date:  2011-11-09       Impact factor: 8.775

Review 5.  Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.

Authors:  Eleni Bekiari; Konstantinos Kitsios; Hood Thabit; Martin Tauschmann; Eleni Athanasiadou; Thomas Karagiannis; Anna-Bettina Haidich; Roman Hovorka; Apostolos Tsapas
Journal:  BMJ       Date:  2018-04-18

Review 6.  Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives.

Authors:  Federico Boscari; Angelo Avogaro
Journal:  Rev Endocr Metab Disord       Date:  2021-03-23       Impact factor: 6.514

7.  Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas.

Authors:  Steven J Russell; Firas H El-Khatib; David M Nathan; Kendra L Magyar; John Jiang; Edward R Damiano
Journal:  Diabetes Care       Date:  2012-08-24       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.